Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$92.98
-0.6%
$92.07
$79.52
$124.00
$23.65B1.32899,049 shs816,163 shs
Insmed, Inc. stock logo
INSM
Insmed
$118.26
+1.5%
$107.60
$90.39
$212.75
$25.26B0.784.20 million shs3.17 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$93.67
+4.8%
$73.65
$23.30
$105.47
$5.57B2.112.12 million shs1.26 million shs
Veracyte, Inc. stock logo
VCYT
Veracyte
$59.30
+5.7%
$48.17
$22.61
$60.91
$4.48B1.931.36 million shs690,860 shs
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-0.59%-4.68%+7.49%-2.64%-16.82%
Insmed, Inc. stock logo
INSM
Insmed
+1.48%+5.97%+19.41%-23.61%+22.59%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
+4.80%-5.61%+33.70%+95.51%+139.44%
Veracyte, Inc. stock logo
VCYT
Veracyte
+5.67%+3.89%+20.43%+90.74%+118.98%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$92.98
-0.6%
$92.07
$79.52
$124.00
$23.65B1.32899,049 shs816,163 shs
Insmed, Inc. stock logo
INSM
Insmed
$118.26
+1.5%
$107.60
$90.39
$212.75
$25.26B0.784.20 million shs3.17 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$93.67
+4.8%
$73.65
$23.30
$105.47
$5.57B2.112.12 million shs1.26 million shs
Veracyte, Inc. stock logo
VCYT
Veracyte
$59.30
+5.7%
$48.17
$22.61
$60.91
$4.48B1.931.36 million shs690,860 shs
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-0.59%-4.68%+7.49%-2.64%-16.82%
Insmed, Inc. stock logo
INSM
Insmed
+1.48%+5.97%+19.41%-23.61%+22.59%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
+4.80%-5.61%+33.70%+95.51%+139.44%
Veracyte, Inc. stock logo
VCYT
Veracyte
+5.67%+3.89%+20.43%+90.74%+118.98%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
2.74
Moderate Buy$129.1338.87% Upside
Insmed, Inc. stock logo
INSM
Insmed
2.96
Moderate Buy$211.8679.15% Upside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.70
Moderate Buy$84.30-10.00% Downside
Veracyte, Inc. stock logo
VCYT
Veracyte
2.78
Moderate Buy$51.86-12.55% Downside

Current Analyst Ratings Breakdown

Latest TWST, VCYT, BNTX, and INSM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/9/2026
Veracyte, Inc. stock logo
VCYT
Veracyte
Boost Price TargetUnderweight$37.00 ➝ $47.00
7/8/2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
Lower Price TargetOverweight$126.00 ➝ $119.00
7/7/2026
Veracyte, Inc. stock logo
VCYT
Veracyte
UpgradeHoldStrong-Buy
7/6/2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
Reiterated RatingSell (D-)
7/6/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
DowngradeOutperformIn-Line$102.00
6/29/2026
Veracyte, Inc. stock logo
VCYT
Veracyte
Boost Price TargetBuy$45.00 ➝ $65.00
6/29/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetBuy$60.00 ➝ $107.00
6/24/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Reiterated RatingSell (D-)
6/24/2026
Veracyte, Inc. stock logo
VCYT
Veracyte
Reiterated RatingHold (C)
6/24/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetOverweight$65.00 ➝ $95.00
6/16/2026
Insmed, Inc. stock logo
INSM
Insmed
Set Price Target$192.00
(Data available from 7/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$3.25B7.24$1.33 per share70.05$96.59 per share0.96
Insmed, Inc. stock logo
INSM
Insmed
$606.42M42.27N/AN/A$3.46 per share34.18
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$376.57M15.49N/AN/A$7.84 per share11.95
Veracyte, Inc. stock logo
VCYT
Veracyte
$517.15M9.15$1.57 per share37.68$16.57 per share3.58
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-$1.29B-$5.88N/AN/AN/A-44.39%-5.30%-4.62%8/4/2026 (Estimated)
Insmed, Inc. stock logo
INSM
Insmed
-$1.28B-$5.75N/A146.00N/A-144.44%-130.11%-51.57%8/6/2026 (Estimated)
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$77.67M-$1.33N/AN/AN/A-19.85%-26.73%-19.15%8/3/2026 (Estimated)
Veracyte, Inc. stock logo
VCYT
Veracyte
$66.35M$1.0954.4041.47N/A16.25%9.07%8.38%8/5/2026 (Estimated)

Latest TWST, VCYT, BNTX, and INSM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Insmed, Inc. stock logo
INSM
Insmed
-$0.75N/AN/AN/A$390.09 millionN/A
8/5/2026Q2 2026
Veracyte, Inc. stock logo
VCYT
Veracyte
$0.44N/AN/AN/A$144.56 millionN/A
8/4/2026Q2 2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-$2.4088N/AN/AN/A$184.79 millionN/A
8/3/2026Q3 2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.50N/AN/AN/A$114.54 millionN/A
5/7/2026Q1 2026
Insmed, Inc. stock logo
INSM
Insmed
-$0.90-$0.76+$0.14-$0.76$300.81 million$305.96 million
5/5/2026Q1 2026
Veracyte, Inc. stock logo
VCYT
Veracyte
$0.34$0.52+$0.18$0.35$130.36 million$139.07 million
5/4/2026Q1 2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-$2.52-$2.2570+$0.2630-$2.43$207.42 million$136.71 million
5/4/2026Q2 2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.49-$0.71-$0.22-$0.71$107.64 million$110.72 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$1.531.65%N/AN/A N/A
Insmed, Inc. stock logo
INSM
Insmed
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
Veracyte, Inc. stock logo
VCYT
Veracyte
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
0.01
8.80
8.74
Insmed, Inc. stock logo
INSM
Insmed
0.80
4.47
4.10
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
2.70
2.42
Veracyte, Inc. stock logo
VCYT
Veracyte
N/A
9.31
8.92

Institutional Ownership

CompanyInstitutional Ownership
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
15.52%
Insmed, Inc. stock logo
INSM
Insmed
N/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A
Veracyte, Inc. stock logo
VCYT
Veracyte
N/A

Insider Ownership

CompanyInsider Ownership
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
19.20%
Insmed, Inc. stock logo
INSM
Insmed
2.10%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.08%
Veracyte, Inc. stock logo
VCYT
Veracyte
1.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
7,807252.88 million204.33 millionOptionable
Insmed, Inc. stock logo
INSM
Insmed
1,664216.75 million212.20 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99062.27 million60.35 millionOptionable
Veracyte, Inc. stock logo
VCYT
Veracyte
79079.79 million78.68 millionOptionable

Recent News About These Companies

Veracyte (NASDAQ:VCYT) Reaches New 12-Month High - Here's Why

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioNTech stock logo

BioNTech NASDAQ:BNTX

$92.98 -0.55 (-0.59%)
Closing price 07/9/2026 04:00 PM Eastern
Extended Trading
$92.94 -0.05 (-0.05%)
As of 07/9/2026 05:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Insmed stock logo

Insmed NASDAQ:INSM

$118.26 +1.73 (+1.48%)
Closing price 07/9/2026 04:00 PM Eastern
Extended Trading
$118.94 +0.68 (+0.58%)
As of 07/9/2026 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$93.67 +4.29 (+4.80%)
Closing price 07/9/2026 04:00 PM Eastern
Extended Trading
$95.67 +2.00 (+2.14%)
As of 07/9/2026 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Veracyte stock logo

Veracyte NASDAQ:VCYT

$59.30 +3.18 (+5.67%)
Closing price 07/9/2026 04:00 PM Eastern
Extended Trading
$59.25 -0.05 (-0.08%)
As of 07/9/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.